Uni-Bio Science Group (HK690) 联康生物科技集团

Uni-Bio Science Group Limited is a company listed on the main board of The Stock Exchange of Hong Kong (SEHK: 0690). The core business of the Company and its subsidiaries is the R&D, manufacturing and sales of innovative biologic products that treat human diseases. Uni-Bio is headquartered in Hong Kong and its main operations are in mainland China. The Group is strongly focused on R&D and has highly qualified team located in Guangdong province. It also has two GMP-certified manufacturing facilities in Beijing and Shenzhen, manufacturing the company’s marketed products - Voriconazole and EGF franchise, respectively. Currently, the Group has two new prescription drugs that have completed all clinical trials –rhExtendin-4 and rhPTH 1-34. The Group’s corporate philosophy is to achieve better human health by bringing high quality science and treatment to patients. To this end, the Group is deeply dedicated to serving patients better through partnering. Ultimately, becoming the “Partner of Choice” in China, bringing cost-effective and important treatments into China.

Hong Kong, Central and Western
Founded in unknown
11-50 employees

Uni-Bio Science Group Limited is a company listed on the main board of The Stock Exchange of Hong Kong (SEHK: 0690). The core business of the Company and its subsidiaries is the R&D, manufacturing and sales of innovative biologic products that treat human diseases. Uni-Bio is headquartered in Hong Kong and its main operations are in mainland China. The Group is strongly focused on R&D and has highly qualified team located in Guangdong province. It also has two GMP-certified manufacturing facilities in Beijing and Shenzhen, manufacturing the company’s marketed products - Voriconazole and EGF franchise, respectively. Currently, the Group has two new prescription drugs that have completed all clinical trials –rhExtendin-4 and rhPTH 1-34. The Group’s corporate philosophy is to achieve better human health by bringing high quality science and treatment to patients. To this end, the Group is deeply dedicated to serving patients better through partnering. Ultimately, becoming the “Partner of Choice” in China, bringing cost-effective and important treatments into China.

Company Information

Industry
Company Type
Public Company
Founded
unknown
Employee Range
11-50
Revenue Range
Not available

Location

Address
20 science park east avenue Shatin
City
Hong Kong
Region
Central and Western
Postal Code
Country
Hong Kong

Web Presence

Ready to automate your outreach?

Get unlimited access to our company database — complete with detailed profiles, funding info, and tech stacks — and start sending personalized emails with AI-powered follow-ups.

Frequently Asked Questions